MedTrace Logo

Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab

NCT04377295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-05-06

No results posted yet for this study

Summary

This study evaluates the retinal and vascular features in patients with radiation maculopathy under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.

Conditions

  • Radiation Maculopathy

Interventions

DRUG

Ranibizumab 0.5Mg/0.05Ml Oph Inj

All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Gilda Cennamo · Federico II University

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-30
Primary Completion
2019-10-01
Completion
2019-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377295 on ClinicalTrials.gov